Streetbeat News

Regulatory

AAPL

Apple Inc. is facing a new antitrust lawsuit from the U.S. Department of Justice, which could potentially increase consumer demand for alternative smartphones. Entrepreneur Vivek Ramaswamy discussed the lawsuit's implications, suggesting it could open opportunities for new entrants in the smartphone market. The lawsuit accuses Apple of restricting competitors' access to iPhone hardware and software, marking the third antitrust case against the company in 14 years. Apple has vowed to fight the lawsuit, stating it threatens its innovation capabilities.

Portfolio Pulse from Ananya Gairola

March 22, 2024 | 12:34 pm

AAPL

The U.S. Department of Justice (DOJ) has filed a lawsuit against Apple Inc (NASDAQ:AAPL), alleging that the company is using its CarPlay service to dominate the automotive industry by making driving an 'iPhone-centric experience'. The lawsuit claims Apple is restricting competitors' access to iPhone hardware and software features, violating antitrust laws. Apple plans to defend vigorously against the lawsuit, stating it believes the lawsuit is wrong on facts and law.

Portfolio Pulse from Anan Ashraf

March 22, 2024 | 12:17 pm

NVDA

SMH

SOXX

TSM

Taiwan Semiconductor Manufacturing Co (TSM) is set to face a 15% to 25% increase in electricity tariffs in Taiwan starting April 1, as part of a broader move to alleviate financial strain on Taiwan Power Co. This hike is expected to have a minimal impact on TSMC's operations but could pose long-term profitability challenges. The tariff increase is in response to Taiwan Power Co.'s significant losses and rising fuel costs. TSMC's stock value has increased by 51% in the last 12 months, and it is a key supplier to Nvidia Corp (NVDA). Investors can gain exposure to TSMC through the VanEck Semiconductor ETF (SMH) and iShares Semiconductor ETF (SOXX).

Portfolio Pulse from Anusuya Lahiri

March 22, 2024 | 12:16 pm

DDD

3D Systems has received a notice from the NYSE for not filing its Form 10-K on time. The company has until September 15, 2024, to file the Form 10-K with the SEC to regain compliance.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 12:04 pm

AAPL

FDX

LULU

NKE

QQQ

RDDT

SPY

TSLA

U.S. stocks are poised for a strong finish to the week, buoyed by rate-cut optimism and anticipation of Fed Chair Powell's speech. The S&P 500's rally this year is deemed 'perfectly normal' by analysts, following a downturn in the midterm year. Futures are up in premarket trading, with notable movements in individual stocks like FedEx, Lululemon, NIKE, and Tesla following earnings announcements and production news. Global markets show mixed reactions, with commodities and bonds also displaying varied trends.

Portfolio Pulse from Shanthi Rexaline

March 22, 2024 | 11:38 am

NVS

VGK

On 21 March 2024, the CHMP recommended granting marketing authorization for Novartis' Fabhalta1, aimed at treating Paroxysmal Nocturnal Haemoglobinuria.

Portfolio Pulse from Charles Gross

March 22, 2024 | 11:15 am

NVO

VGK

On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for Novo Nordisk's Awiqli, intended for the treatment of diabetes mellitus. This recommendation is a crucial step towards the commercial availability of Awiqli in the European market.

Portfolio Pulse from Charles Gross

March 22, 2024 | 11:13 am

AAPL

Apple Inc. (NASDAQ:AAPL) has filed a patent for an all-glass MacBook Pro, potentially featuring a touchscreen. The patent suggests the use of glass for the MacBook Pro's back and possibly for the front and back surfaces of the display, with a metal housing for the sides. This development is part of Apple's exploration into innovative display technologies, including touchscreens for MacBook computers and foldable screens for iPads or MacBooks.

Portfolio Pulse from Ananya Gairola

March 22, 2024 | 11:10 am

PFE

Pfizer Inc. (NYSE:PFE) received a positive opinion from the CHMP of the EMA for its novel antibiotic combination, EMBLAVEO®. This recommendation is for the treatment of adult patients with multidrug-resistant infections, including cIAI, HAP, VAP, and cUTI, with limited treatment options. The MAA for EMBLAVEO® underwent an accelerated assessment due to its significance for public health and therapeutic innovation.

Portfolio Pulse from Charles Gross

March 22, 2024 | 11:09 am

TECH

Bio-Techne has been granted European IVDR certification for its diagnostic test designed to monitor Chronic Myeloid Leukemia. This certification allows the company to market and sell the test in European markets, potentially expanding its customer base and increasing revenue from its diagnostic products segment.

Portfolio Pulse from Benzinga Newsdesk

March 22, 2024 | 11:07 am